Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Decreases By 15.8%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 61,515 shares, a decrease of 15.8% from the December 31st total of 73,076 shares. Currently, 4.6% of the shares of the stock are sold short. Based on an average trading volume of 81,521 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 81,521 shares, the short-interest ratio is currently 0.8 days. Currently, 4.6% of the shares of the stock are sold short.

Galmed Pharmaceuticals Trading Down 5.3%

NASDAQ GLMD opened at $0.71 on Monday. The business’s 50-day moving average price is $0.89 and its 200 day moving average price is $1.24. Galmed Pharmaceuticals has a twelve month low of $0.70 and a twelve month high of $3.50. The company has a market capitalization of $1.17 million, a PE ratio of -2.22 and a beta of 0.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.